Rameda is established by a group of Gulf investors with the intention of creating one of the region’s largest pharmaceutical operations; commissions the construction of its first state-of-the-art facility.
Rameda enters into an agreement with Alcon, the world’s second-largest manufacturer of consumer vision care products, to manufacture their ophthalmology products under license. In coordination with Alcon, Rameda builds one of the highest quality eye drops production facilities in the region.
Compass Capital leads a consortium of investors in fully acquiring Rameda, working to make Rameda a leading player in the pharmaceutical industry. A new executive management team with multinational experience is hired to complement the existing team and oversee a successful transition at the company.
Facility upgrades continue with the redesign of Rameda’s cephalosporin injectable plant and penicillin plant to increase capacity for injectables, tablets, capsules, and macro dosing production.
Rameda launches X-tension, one of the Group’s leading products, ranking number three in its therapeutic class (ATC 5) as of 2018.
Rameda establishes a state-of-the-art warehouse for penicillin and cephalosporin, as well as independent labs and employee facilities including an in-house restaurant. This brought the facilities into compliance with the latest GMP requirements, thus creating a modern production facility complete with all the support functions necessary
German designer M+W is commissioned to redesign Rameda’s facility, upgrading it to conform with the latest design requirements of the pharmaceutical industry’s Good Manufacturing Practices (GMP).
The company engages multinational CMO audits and foreign ministries of health to register facilities to open potential export markets, reaffirming its high standards of quality.
Rameda launches Joypox, one of the Group’s leading products, and ranks number 1 in its therapeutic class. *according to IMS Data as of 2018.
Introduces a new area for the production of sterile plastic ampoules using Blow Fill Seal technology.
Rameda becomes Egypt’s fastest-growing pharmaceutical company among top pharma players.
Rameda embarks on a c.EGP 250 million expansion plan to the production facilities increasing its production capacity and fueling growth.
Rameda launches Optaminess, one of the Group’s leading products, which is a dietary supplement used for kidney dialysis treatment and ranked number 2 in its therapeutic class (ATC 5). *according to IMS Data as of 2018.
Rameda completes and commissions the upgraded facilities. This includes redesign of solid for production area, addition of Blow Fill Seal, addition of two lyophilized production areas composed of two lines, adding of second cephalosporin injectable line and additional upgrade in solid.
Rameda completes listing its shares on EGX
Rameda acquires Recoxibright, a nonsteroidal anti-inflammatory analgesic molecule, marking the company’s largest molecule acquisition to date. Rameda received its final commercial manufacturing licenses to produce and sell Remdesivir and Anviziram, in Egypt.